from the world's big
A new spray may help treat the deadly white-nose syndrome
Bats are being subjected to a deadly plague that may be threatening their existence. However, a new bacterial spray may help fight the fungus responsible.
- Since 2006, white-nose syndrome has killed millions and millions of bats, threatening many species with extinction.
- Bats may not be everybody's idea of a cute and cuddly animal, but losing them would be devastating to the ecosystem.
- Fortunately, researchers are hard at work trying to uncover a means of dealing with this fungal disease. One such treatment is the use of the antifungal bacteria Pseudomonas fluorescens.
Since arriving in North America in 2006, Pseuodgymnoascus destructans has been wreaking havoc in bat populations. The fuzzy white fungus rapidly infects bats, tending to cluster around the nocturnal mammals' noses. Hence, the disease it causes is best known as white-nose syndrome.
Once P. destructans infects a bat colony, it wipes out about 90 percent of the colony on average. By agitating bats during the winter months when they're meant to be hibernating, P. destructans forces them to emerge early and expend the energy they need to get through the winter. As a result, the cold-loving fungus has killed millions and millions of bats since 2006. Bats may not be the cutest or most popular animal out there, but the sheer scale of this plague threatens to drive bat species to extinction and thoroughly throw our ecosystem out of whack.
"This disease has really just been devastating," said ecologist Joseph Hoyt. "We've essentially removed our dominant nighttime insect predator." That's why Hoyt and colleagues conducted an experiment in a Wisconsin mine to test out a new treatment for white-nose syndrome: Pseudomonas fluorescens, an inherently antifungal bacteria. Through their efforts, described in Scientific Reports, Hoyt's team were able to increase survivorship in bats by more than fivefold.
Spraying bats with beneficial bacteria
A little brown bat afflicted with white-nose syndrome.
Flickr user U.S. Fish and Wildlife Service Headquarters
P. fluorescens is frequently used in agricultural contexts as an antifungal agent and has also been used to treat similar fungal infections in amphibians. What's better, P. fluorescens is naturally present on bats already, so using it for treatment posed little risk of introducing additional threats to bat species.
For these reasons, P. fluorescens was an attractive subject for Hoyt and colleagues. To conduct their experiment, they picked a mine in Wisconsin that served as a hibernacula — a fancy term referring to caves in which bats hibernate over winter — for a colony of Myotis lucifugus, or the little brown bat.
Little brown bats were once one of the most common species in the northeastern U.S., but white-nose syndrome is quickly changing that. In fact, the year before in the very same mine that Hoyt and colleagues had chosen, there had been 226 little brown bats. On the year the researchers chose to conduct their experiment, that number had dwindled to just 82.
Prior to the start of winter, the researchers collected 60 bats from the mine with roughly 30 each to serve in the control and treatment groups, respectively. All bats were given a tag that would trigger a transponder near the entrance of the cave, alerting the researchers to a bat's movements in and out of the cave and, in theory, to when the bats immerged from hibernation. In this way, the researchers could determine whether a bat had died during hibernation or whether white-nose syndrome had driven them out of the cave early. If the bats failed to return, they were presumed to have died. To confirm this, the researchers searched through all known sites within 50 kilometers of the focal mine to find any tagged bats who had immigrated to a new hibernaculum, but this proved not to be the case.
Significant progress, significant challenges
"Bats are really difficult to work with," said Hoyt, "so being able to pull out some meaningful results from this work was a huge win for us." And the results were striking. In the control group, only about 8 percent of bats survived the winter. But in the group treated with P. fluorescens, nearly 50 percent of bats survived. "It's definitely exciting news," said Hoyt. "Fifty percent is great. It's not 100% like we would hope, unfortunately, but I am not sure we'll ever get there."
Significant challenges remain before we can solve white-nose syndrome. For one, Hoyt and colleagues applied their treatment slowly, tediously, to just a handful of bats. Bat colonies, however, can reach the thousands; treating huge colonies, who are at the greatest risk for white-nose syndrome, will be difficult. What's more, P. fluorescens only helped save half of the bat population. Assuming this number holds in more large-scale treatments, bats still can't afford to lose half of their colony members each winter. With more work and any luck, however, future researchers will be able to come up with a solution to treating bat colonies en masse and potentially discover the right combination of antifungal treatments to prevent death by white-nose syndrome entirely.
Ready to see the future? Nanotronics CEO Matthew Putman talks innovation and the solutions that are right under our noses.
Innovation in manufacturing has crawled since the 1950s. That's about to speed up.
A scientist in Sweden makes a controversial presentation at a future of food conference.
- A behavioral scientist from Sweden thinks cannibalism of corpses will become necessary due to effects of climate change.
- He made the controversial presentation to Swedish TV during a "Future of Food" conference in Stockholm.
- The scientist acknowledges the many taboos this idea would have to overcome.
Depiction of cannibalism in the Medieval ages.
Soylent Green (1973) Official Trailer - Charlton Heston, Edward G Robinson Movie HD<span style="display:block;position:relative;padding-top:56.25%;" class="rm-shortcode" data-rm-shortcode-id="fc218a17afaf87b09fd01ba2320a7375"><iframe type="lazy-iframe" data-runner-src="https://www.youtube.com/embed/N_jGOKYHxaQ?rel=0" width="100%" height="auto" frameborder="0" scrolling="no" style="position:absolute;top:0;left:0;width:100%;height:100%;"></iframe></span>
President Vladimir Putin announces approval of Russia's coronavirus vaccine but scientists warn it may be unsafe.
A new coronavirus vaccine on display at the Nikolai Gamaleya National Center of Epidemiology and Microbiology in Moscow, Russia.
Credit: Alexander Zemlianichenko Jr/ Russian Direct Investment Fund via AP
Medical workers draw blood from volunteers participating in a trial of a coronavirus vaccine at the Budenko Main Military Hospital outside Moscow, Russia.
Credit: Russian Defense Ministry Press Service via AP
A report from the New York Times raises questions over how the teletherapy startup Talkspace handles user data.
- In the report, several former employees said that "individual users' anonymized conversations were routinely reviewed and mined for insights."
- Talkspace denied using user data for marketing purposes, though it acknowledged that it looks at client transcripts to improve its services.
- It's still unclear whether teletherapy is as effective as traditional therapy.
Talkspace.com<p>Former employees also questioned the legitimacy of certain interventions by the company into client-therapist interactions. For example, after one therapist sent a client a link to an online anxiety worksheet, a company representative instructed her to try to keep clients inside the app.</p><p style="margin-left: 20px;">"I was like, 'How do you know I did that?'" Karissa Brennan, a therapist who worked with Talkspace from 2015 to 2017, told the Times. "They said it was private, but it wasn't."</p><p>Other former employees said the company would pay special attention to its "enterprise partner" clients, who worked at companies like Google. One therapist said Talkspace contacted her for taking too long to respond to Google clients.</p><p>Talkspace responded to the Times with a Medium <a href="https://medium.com/@founders_22883/talkspace-founders-respond-to-a-new-york-times-article-78d6f5c45c59" target="_blank">post</a>, which claimed the Times report contained false and "uninformed assertions."</p><p style="margin-left: 20px;">"Talkspace is a HIPAA/HITECH and SOC2 approved platform, audited annually by external vendors, and has deployed additional technologies to keep its data safe, exceeding all existing regulatory requirements," the post states.</p>